Member Info for AquaeSulis01

My guess at half year revenues are Croda - £750K, BTS - £2.1M, Derm - £1.1M and Axis £300k giving total £4.25M. Superdrug rollout started later than planned and has still not completed for the phase 1 stores so am not expecting much of a revenue uplift.

"It is a shame we have personal insults, they are not needed, lets keep it respectful and on topic." nice try Toyin, sadly didn't last too long.

Anyway to get back on topic and to the TW Headline that led to this thread, I would suggest that if TW went back over his own research that led to his final "Compelling Strong Buy" recommendation he would fully understand why MD sees such an exciting proposition here as summarised in Tom's own words:

"5. At the very worst it strikes me as though Skins will, by 2027, will be making several millions pounds profit which is more than enough to justify a £45M Market Cap at 20p BUT:

. One can paint a scenario where within four or five years Skins is making profits of ten, twenty or thirty million pounds and is growing that number. I’d hope it would use £500,000 of those profits going from AIM to the Main market. The smallest company in the FTSE 250 s currently capitalized at £276M. Were Skins making even £15 million, a PE of 20 would see it in the FTSE 250, ceteris paribus. Index funds would be buying, who knows what could happen as profits continue to climb.

6. I am not betting the ranch on the last scenario. But the worst case scenario could, plausibly, see the shares ten bag from here. And it would not take five years to do that. Markets look ahead. And that is why the shares are a compelling STRONG BUY. "

Thankyou for the clarification shychap now seems that we're all on the same page and supportive of elric's attempt to improve engagement with shareholders via setting up and managing a Q&A type Forum; let's wish him luck and give him and the Company the breathing space to consider.

Shychap, I think you confuse elric with the self proclaimed Sheriff of Aim. What Elric is trying to put in place on behalf of all shareholders is a forum for Investor Q&A Summaries which I believe is iaw the principles of the QCA Code for which you are such an advocate so why not try and support him in that aim rather than undermine his efforts?

Just wish the CEO's name was Xu Pi rather than Harry Anagnostaras-Adams as the wet signature would have been a lot quicker to write

Bel, take the royal we to mean you are back as a shareholder. If you PMing elric on substack i am sure he will provide you with access

Shychap, I prefer to debate and correct where there is error rather than filter.

Regarding your remark to Elric "I respectfully suggest that your job is to make him accountable – not to protect him." I can only think it was the late hour you posted that confused you into thinking it was Elric's job rather than the Non-exec on the Board; Elric is attempting to act as a conduit to seek answers via the Company to reasonable and burning questions on matters that all investors want clarity on for which he should be applauded

PG, not helpful mate, this move to improve comms is about building bridges not blowing them up. All I am suggesting is that whilst folks will remain sceptical until they start to see improvements, at least keep your powder dry until you have a chance to evaluate whether things are improving rather than trying to strangle any new initiative upfront

Shychap, you really are turning into a right old curmudgeon, why don't you just acknowledge the gesture as the positive step in the right direction for comms that it is. I subscribe to lemmings and reached out to Elric to consider making sbtx content available to all when he posts the links on the BB.

Let me make it clear, Elric is not being paid by the Company and I can ensure you that many articles produced by Elric in the past have contained criticism where he felt it deserved albeit without the emotional baggage that a certain paywall favourite of yours carries with it. Elric also at least attempts to get answers to Investors questions and he is exploring trying to do this for all going forward but the continual sniping by the likes of yourself will undoubtedly make him question whether it is worth pursuing this avenue.

Disappointing you didn't receive a Company response at the time Toyin, at the moment there is a symmetry across the axis products so maybe they need longer to consult and think about how to manage a divergence going forward?

Shychap, "The fundraise was also for general working capital to ensure that the accounts got a clean sign-off from the auditor", not sure I agree with that. What you haven't factored in is the estimated £1M capex used for the Superdrug launch.

Toyin,

Noted, but as the order had to be placed before End June to meet the Superdrug wk 35 deadline, surely such a late product change could be accommodated or risked?

Hi ox and happy New Year to you too. The reference to the Axisbiotix product is to convert axibiotix-ac into a capsule which would be more convenient to take and occupy a smaller package and hence shelf space which I suspect ideally SA would like to have achieved prior to the Superdrug launch.

One thing at a time; first up upgrade BTS site, restart Project Epiderm and then incorporate SBTX technology into Dermatonics products:

"From the EOY Results

As detailed as part of the fundraise in June, we will be using some of these funds to enhance the BTS site. This will allow us to build this site into a facility that can support the packaging and enhancement of our AxisBiotix™ product offering extending its capacity and capabilities to service a broader range of contracts including medical device-certified products. This would also allow the Group to become more efficient and be able to produce different grades of cosmetic and medical products. Each phase of the investment plan will only commence if milestones based on an increase in profitability are triggered; we will fund this plan through internal means only rather than raise more funds.

Research and Development

SkinBioTherapeutics has a number of R&D projects underway with the University of Manchester. With the amount of activity going on in the commercial parts of the business and the integration of our recent acquisitions, activities around R&D have been put on hold until the Board has determined which programmes have the greatest potential and value. The current projects are:

- MediBiotix - developing SkinBiotix™ for accelerated wound closure, a medical device application. The programme is called Project Epiderm. This work is being undertaken by Professors Cruikshank and McBain at the University of Manchester and has been joint funded by SBTX and grant funding.

Investor Meets 22nd March 2024 -Q&A

Q4 Has the Project Epiderm been launched with incorporation of the skin bacterium into the Dermatonics Once Heel Balm in mind?

Yes, of course we talked about hard to heal wounds and one of those bigger areas of hard to heal wounds are diabetic foot ulcers. That is an area of expertise of the Dermatonic’s Team, in particular their Clinical lead in-house. It is a conversation we have had and part of the reason we want to explore this deeply and is absolutely is one of the things that is guiding us through this Project, so the answer to that is yes."

Net, we are in full agreement about SBTX and it by far my biggest Investment. Opti as a Company I consider too high risk to invest in, not because sweetbiotix hasn't the potential to be as big as zenakine is for SBTX but because there is no clear timeline for the product launching and hence revenues being received. Opti is in a similar position SBTX was in a couple of years ago when it had one loss making product in Axisbiotix-ps and it had to rely on fundraises to stay afloat. The issue Opti faces is will the launch of sweetbiotix happen before it runs out of Assets to sell to balance the books because I have no faith that slimbiome/wellbiome etc will take off now that weight loss jabs and pills are king rather than meal replacement shakes?

Regarding sugar companies, they would certainly have been doing their best to stimy the promotion of any threat to the sales of sugar before, but the ability of the new enzyme to not only reduce waste by 90% and work on sucrose as well as mogrosides and stevia should be a game changer for sweetbiotix products; we just don't know how long it will take to scale-up and test.

It's not bs nocheesecake, if the US took Military action to seize Greenland then the immediate impact (0-3 mths):

- All mining licenses issued by Greenland/Denmark would enter legal limbo.

- A US military administration would likely freeze all foreign‑issued licenses pending review.

- Amaroq’s rights could be suspended, renegotiated, or voided.

However, the likelihood of the US taking Military action against a territory belonging to a NATO member is remote, it is coercive language I suspect to achieve "- A Compact of Free Association" a treaty-based relationship where:

- The smaller state is sovereign and internationally recognised.

- It chooses to associate with a larger state.

- The larger state (e.g., the US) typically provides:

- Defence and security guarantees

- Financial assistance

- Access to certain domestic programs

- In return, the smaller state grants:

- Full defence authority to the larger state

- Certain strategic rights (e.g., military basing, airspace control)

This is the model used by the Marshall Islands, Micronesia, and Palau under COFA.

Why when Denmark is a current NATO member?

It does not give the US:

- Sovereign authority

- Exclusive basing rights

- Control over airspace

- Control over ports

- Control over mineral policy

- Control over foreign investment screening

- Control over Arctic shipping lanes

Under NATO, Greenland remains Danish sovereign territory, and Denmark decides:

- Who can operate there

- What military infrastructure is allowed

- What mining projects are approved

- What foreign powers can invest

This is exactly what the US wants to change.

Sold out here too mol.

https://www.1mg.com/otc/pheet-cracked-heel-balm-with-manuka-honey-otc1135383

Net, I have to correct you on two points, I am an ex Opti shareholder and owned the shares for a number of years and a product that tastes like sugar but is actually good for you is not ridiculous but a holy grail and your unresearched and hence uniformed comments remind me of Bazza's comments about zenakine when he described it as an expensive version of horlicks

Net with respect you are talking nonsense. The issue with sweetbiotix isn't that it is worthless but that its commercial launch has undergone so many false dawns no one believes it is going to happen anytime soon. If it does then Opti will multibag from its current sp but it is a BIG IF. The unnamed US Partner has paid out over £550k in pre-launch royalties for sweetbiotix so they obviously see value in its. For the re order Istill no longer hold a single Opti share so have no interest in talking the Company up

Mol, whilst there have undoubtedly been a series of missteps from SA, I don’t think folks have given enough credit to him for keeping the Company financed during his initial period in charge where there was no or little revenue coming in and high R&D commitments. He joined Apr 2019, and raised £4M at 16p at a time when 2019 EOY Results showed zero revenue and £1.36M loss. 2020 and 2021 saw further losses of £1.62M and £1.5M respectively with again no revenue and led to a further equity raise of £2.5M again at 16p.

2022 and 2023 saw first axisbiotix revenues of £75K and £132K whilst losses increased to £2.72M and £3M as marketing and inventory costs kicked in alongside still substantial R&D requiring a further fundraise of £3M at 19p.

At this point, with the continuing delay to the anticipated Skinbiotix Croda launch, SA decided to go down the Acquisition route as an insurance policy and to prepare for longer term growth on the back of the skinbiotix technology; this lead to 2024 revenues of £1.2M and a loss of £2.9M and finally 2025 revenues, excluding Croda of £3.8M and a £1.9M loss excluding the Croda contribution, so progress has been made but with the benefit of the Croda revenues it is now time for him to deliver a net profit in 2026.

Cheers mol. Big prize in India will be sales direct to clinics which I believe the bulk of Umesh Modi sales force are focused on; be interesting to see what the "ROW" sales are in the Interims as compared to the Final Results.

Like others, I am not expecting much from the Superdrug launch, there has been very little marketing and from my own research I believe there is still a fair way to go before phase 1 Stores are fully rolled out.

Croda blowing the doors off thank goodness.